previou
microarraybas
studi
acut
respiratori
distress
syndrom
ard
perform
use
variou
model
mimic
diseas
pathogenesi
complex
pathophysiolog
respons
direct
indirect
lung
injuri
ard
difficult
reconstruct
experiment
condit
thu
direct
analysi
ard
patient
blood
may
provid
valuabl
inform
investig
genomewid
gene
express
profil
pair
whole
blood
sampl
patient
ard
n
acut
stage
within
diagnosi
recoveri
stage
ard
around
icu
discharg
among
differenti
express
gene
peptidas
inhibitor
encod
elafin
potent
neutrophil
elastas
inhibitor
largest
foldchang
chang
acut
stagerecoveri
stage
express
indic
downregul
acut
stage
ard
examin
plasma
level
patient
ard
atrisk
control
subject
cohort
coincid
microarray
find
lower
gene
express
lower
plasma
acutestag
plasma
level
statist
signific
differ
among
prediagnosi
day
diagnosi
postdiagnosi
group
anova
p
trend
decreas
preto
postdiagnosi
group
time
cours
plasma
decreas
well
correl
cours
earli
ard
develop
pearson
correl
coeffici
p
consid
coval
bind
extracellular
matrix
lung
circul
may
provid
use
clinic
marker
monitor
earli
develop
ard
may
implic
ard
treatment
acut
respiratori
distress
syndrom
ard
character
intens
inflammatori
respons
direct
indirect
lung
injuri
exposur
result
diffus
alveolar
damag
sever
lifethreaten
hypoxia
risk
factor
develop
ard
includ
condit
commonli
observ
critic
ill
patient
sepsi
trauma
pneumonia
burn
massiv
transfus
pack
red
blood
cell
addit
emerg
viral
diseas
coronaviru
known
caus
sever
acut
respiratori
syndrom
sar
avian
influenza
viru
becom
import
caus
ard
human
potenti
pandem
spread
event
highlight
need
addit
research
improv
understand
pathogenesi
ard
ultim
goal
develop
specif
treatment
genomewid
gene
express
profil
use
microarray
technolog
appli
success
studi
human
diseas
pathogenesi
exampl
includ
discoveri
new
cancer
subtyp
differ
prognosi
respons
therapi
well
gener
new
hypothes
diseas
pathogenesi
asthma
pulmonari
fibrosi
ard
howev
given
inher
difficulti
collect
rna
sampl
patient
ard
previou
microarraybas
studi
ard
perform
use
variou
model
mimic
pathogenesi
acut
lung
injuri
ali
cell
cultur
anim
model
ex
vivo
pulmonari
tissu
analysi
healthi
human
volunt
although
similar
pattern
differenti
express
report
among
independ
studi
ard
diseas
model
direct
evid
support
find
actual
diseas
state
complex
pathophysiolog
respons
direct
indirect
lung
injuri
ard
difficult
reconstruct
singl
experiment
stimulu
studi
microarray
express
analys
sampl
patient
ard
may
provid
valuabl
inform
complex
inflammatori
respons
ard
previous
publish
evid
pairedsampl
studi
design
detect
gene
express
chang
total
rna
whole
blood
individu
occup
expos
inhal
particul
even
though
particulateinduc
chang
small
compar
persontoperson
variat
followup
studi
confirm
find
suggest
particulateinduc
effect
gene
express
profil
transient
diminish
within
hour
exposur
exhibit
doserespons
pattern
unpublish
data
base
previou
experi
assess
global
gene
express
profil
human
blood
sampl
appli
strategi
use
microarray
analysi
explor
potenti
candid
gene
identifi
potenti
downstream
protein
product
use
biomark
ard
start
exploratori
studi
genomewid
gene
express
whole
blood
sampl
patient
ard
hypothesi
ardsrel
differenti
gene
express
acutestag
recoverystag
ard
result
gene
express
profil
investig
plasma
sampl
cohort
sinc
whole
blood
sampl
complex
composit
heterogen
cell
type
composit
vari
differ
pathophysiolog
condit
possibl
differ
percentag
certain
subtyp
blood
cell
acut
stage
recoveri
stage
ard
could
sole
result
observ
differenti
express
whole
blood
express
profil
howev
also
possibl
nondifferenti
studi
suggest
possibl
protect
role
elafin
acut
respiratori
distress
syndrom
ard
circul
may
provid
use
clinic
marker
monitor
earli
develop
ard
may
implic
ard
treatment
express
whole
blood
could
result
compound
effect
differ
percentag
blood
cell
subtyp
truli
differenti
express
certain
subtyp
although
truli
differenti
express
subtyp
cell
later
situat
could
reveal
adjust
cell
subtyp
overal
global
differenti
express
whole
blood
meaning
ard
biomark
explor
studi
conduct
within
ongo
molecular
epidemiolog
ard
project
massachusett
gener
hospit
mgh
harvard
school
public
health
boston
massachusett
studi
start
approv
human
subject
committe
institut
studi
subject
recruit
patient
admit
one
four
adult
intens
care
unit
icu
mgh
describ
previous
elig
subject
patient
admit
icu
least
one
risk
factor
develop
ard
sepsi
septic
shock
trauma
pneumonia
aspir
massiv
transfus
pack
red
blood
cell
prbc
defin
unit
prbc
h
admiss
patient
follow
prospect
icu
develop
ard
patient
develop
ard
defin
american
european
consensu
committe
aecc
criteria
identifi
ard
case
control
subject
identifi
atrisk
patient
meet
criteria
ard
stay
icu
prior
histori
ard
baselin
clinic
inform
vital
sign
laboratori
test
result
first
hour
icu
admiss
collect
calcul
acut
physiolog
chronic
health
evalu
apach
iii
score
addit
blood
collect
dna
extract
icu
stay
plasma
sampl
also
collect
longterm
storag
base
origin
protocol
two
plasma
sampl
collect
recruit
subject
first
sampl
collect
first
hour
icu
admiss
second
sampl
collect
day
first
collect
written
inform
consent
obtain
subject
appropri
proxi
patient
previou
evid
show
pairedsampl
studi
design
could
minim
biolog
variabl
among
individu
compar
precis
gene
express
profil
differ
exposur
state
especi
circumst
expect
express
variat
less
interperson
variat
appli
similar
pairedsampl
studi
design
exploratori
microarray
studi
blood
sampl
two
blood
sampl
collect
patient
ard
given
situat
uncertain
time
ard
develop
atrisk
icu
patient
extrem
difficulti
obtain
full
collabor
patient
medic
staff
icu
variabl
cours
diseas
progress
extrem
difficult
collect
sampl
exactli
two
arbitrarili
set
time
point
also
practic
imposs
fraction
blood
cell
time
without
introduc
extra
ex
vivo
variat
therefor
hypothesi
gener
purpos
compar
differ
gene
express
whole
blood
total
rna
sampl
acut
stage
ard
collect
within
ard
diagnosi
recoveri
stage
collect
within
period
icu
discharg
even
though
larg
time
variat
pair
sampl
collect
protocol
sampl
collect
process
whole
blood
total
rna
extract
qualiti
assess
describ
previous
rna
sampl
hybrid
affymetrix
human
genom
genechip
affymetrix
santa
clara
ca
microarray
core
facil
danafarb
cancer
institut
boston
pair
rna
sampl
collect
subject
process
togeth
one
batch
microarray
analysi
minim
inher
variat
sinc
gene
express
profil
whole
blood
total
rna
compound
effect
hemoglobin
rna
variou
subset
white
blood
cell
use
dnachip
analyz
dchip
http
wwwdchip
org
softwar
appli
invari
set
gene
normal
calcul
express
valu
across
microarray
normal
raw
microarray
signal
assumpt
subset
gene
constant
express
among
subtyp
cell
detect
call
gene
present
call
absent
call
rna
sampl
carri
affymetrix
ma
softwar
use
onesid
wilcoxon
signedrank
algorithm
obtain
highqual
microarray
data
pair
rna
sampl
subject
although
focus
recruit
patient
ard
microarray
analysi
two
subject
misclassifi
origin
patient
ard
meet
aecc
criteria
ard
icu
therefor
exclud
pair
microarray
analysi
addit
one
ard
case
exclud
sinc
first
sampl
collect
day
diagnosi
ard
attempt
standard
time
collect
ardsrel
gene
express
chang
examin
among
eight
remain
pair
rna
sampl
baselin
characterist
subject
shown
tabl
total
probe
set
affymetrix
microarray
subset
probe
set
present
call
test
array
use
microarray
data
analysi
gene
alter
express
two
time
point
identifi
initi
screen
averag
fold
chang
pair
sampl
larger
less
test
gene
use
onesid
pair
test
p
valu
cutoff
signific
function
cluster
analys
identifi
gene
carri
annot
defin
gene
ontolog
consortium
go
http
wwwgeneontologyorg
use
nonredund
gene
list
affymetrix
microarray
analysi
download
affymetrix
websit
march
genenot
softwar
http
combiocsbrandeisedugenenotesindexhtm
use
identifi
go
biolog
process
significantli
enrich
alter
gene
bonferroni
correct
valid
microarray
data
taqman
appli
biosystem
foster
citi
ca
quantit
realtim
revers
transcriptas
polymeras
chain
reaction
rtpcr
perform
avail
pair
rna
sampl
six
subject
taqman
probe
avail
assay
demand
use
analys
express
level
five
target
gene
includ
hpgd
well
three
endogen
control
gene
actb
accord
manufacturersuggest
procedur
briefli
cdna
first
synthes
approxim
mg
rna
reaction
volum
use
high
capac
cdna
archiv
kit
appli
biosystem
quantit
rtpcr
perform
synthes
cdna
triplic
abi
prism
sequenc
detect
system
appli
biosystem
three
simultan
detect
intern
control
gene
show
lowest
level
intraassay
variat
chosen
normal
rtpcr
result
rel
express
level
pair
rna
sampl
determin
use
ddct
method
valu
first
rna
sampl
acut
stage
ard
pair
calibr
sinc
studi
subject
molecular
epidemiolog
studi
ard
prospect
follow
develop
ard
icu
admiss
plasma
sampl
collect
first
day
icu
stay
plasma
sampl
patient
ard
collect
period
day
ard
diagnosi
uniqu
featur
studi
design
enabl
us
conduct
nest
studi
compar
plasma
preelafin
fulli
function
precursor
elafin
level
among
three
ard
sampl
group
includ
prediagnosi
group
period
ard
diagnosi
dayofdiagnosi
group
within
h
diagnosi
postdiagnosi
group
period
diagnosi
addit
comparison
ard
case
atrisk
control
subject
total
subject
includ
patient
ard
atrisk
control
subject
plasma
sampl
avail
analysi
select
patient
ard
includ
subject
prediagnosi
group
subject
dayofdiagnosi
group
well
subject
randomli
select
postdiagnosi
group
twentythre
atrisk
control
subject
randomli
select
pair
plasma
sampl
first
sampl
collect
first
hour
icu
admiss
second
sampl
collect
day
later
plasma
sampl
store
analysi
plasma
matrix
metalloproteinas
mmp
level
quantifi
duplic
use
human
preelafinskalp
elisa
test
kit
cell
scienc
canton
human
immunoassay
kit
millipor
billerica
accord
manufactur
recommend
protocol
baselin
characterist
group
compar
use
chisquar
test
categor
variabl
student
test
normal
distribut
continu
variabl
correl
microarray
express
data
quantit
rtpcr
data
estim
pearson
correl
test
sinc
plasma
level
skew
distribut
natur
log
transform
data
use
analys
plasma
level
among
three
ard
sampl
group
one
control
sampl
group
compar
use
anova
analysi
comparison
individu
sampl
group
conduct
use
student
test
p
valu
cutoff
bonferroni
correct
multipl
comparison
relationship
ard
plasma
level
sampl
date
rel
ard
diagnosi
investig
stepwis
multivari
linear
regress
analys
defin
associ
covari
sampl
date
rel
ard
diagnosi
forc
covari
model
candid
covari
includ
age
sex
apach
iii
score
icu
admiss
histori
steroid
use
predeposit
clinic
complic
includ
sepsi
septic
shock
diabet
chronic
liver
diseas
pneumonia
trauma
laboratori
test
result
icu
admiss
includ
hematocrit
wbc
count
platelet
count
serum
sodium
serum
potassium
serum
urea
nitrogen
serum
creatinin
serum
glucos
serum
albumin
serum
bilirubin
serum
bicarbon
criterion
covari
select
p
statist
analys
perform
use
sa
statist
softwar
packag
version
sa
inc
cari
nc
studi
compar
differ
gene
express
whole
blood
total
rna
sampl
acut
stage
ard
collect
within
ard
diagnosi
recoverystag
collect
within
period
icu
discharg
eight
pair
microarray
median
period
two
sampl
collect
day
rang
tabl
comparison
gene
express
perform
use
straightforward
approach
foldchang
rank
plu
p
valu
cutoff
prove
reliabl
rank
criterion
gene
select
previou
studi
subset
probe
set
averag
pair
foldchang
larger
identifi
gene
probe
set
significantli
alter
gene
express
compar
recoveri
stage
ard
n
gene
express
lower
level
n
express
higher
level
acut
stage
suggest
mani
gene
suppress
acut
stage
ard
see
tabl
onlin
supplement
complet
list
gene
also
found
subset
gene
larg
chang
express
foldchang
shown
tabl
compar
previou
microarray
analys
whole
blood
pair
rna
sampl
gene
list
greater
chang
express
gene
hgpd
two
probe
set
show
signific
ardsrel
variat
biolog
function
may
associ
gene
demonstr
ardsrel
express
chang
next
investig
go
biolog
process
categori
limit
literatur
mine
medlin
databas
go
analysi
focus
go
term
overrepresent
gene
differenti
express
frequent
expect
chanc
found
go
term
test
significantli
bonferroni
correct
p
multipl
comparison
close
interconnect
go
structur
two
gener
go
categori
respons
stimulu
go
death
go
list
tabl
addit
specif
go
categori
prostaglandin
metabol
go
margin
signific
bonferroni
correct
p
three
gene
hgpd
associ
ardsrel
express
chang
total
gene
identifi
within
three
categori
go
term
respons
stimulu
go
death
go
prostaglandin
metabol
go
addit
list
alter
gene
compar
result
medgen
literatur
mine
medlin
databas
toprank
gene
link
ard
well
ardsrel
mesh
term
includ
neutrophil
leukotrien
prostaglandin
identifi
three
gene
associ
ard
addit
gene
associ
relev
mesh
term
tabl
gene
also
found
signific
go
categori
furthermor
use
medgen
literatur
mine
gene
alter
express
gene
found
directli
link
develop
ard
locat
go
term
respons
stimulu
go
tabl
microarray
result
valid
analyz
five
select
gene
use
quantit
rtpcr
six
subject
enough
pair
rna
sampl
avail
microarray
analysi
three
gene
downregul
gene
upregul
hpgd
gene
acut
stage
ard
chosen
base
larg
differenti
express
acut
stage
recoveri
stage
ard
identifi
repeatedli
medlin
literatur
mine
addit
gene
margin
express
chang
chang
p
encod
enzym
involv
process
inactiv
degrad
leukotrien
gene
chang
foldchang
p
encod
matrix
metalloproteinas
chosen
refer
gene
shown
figur
microarray
quantit
rtpcr
result
show
good
agreement
foldchang
two
time
point
correl
coeffici
test
gene
statist
signific
differ
microarray
rtpcr
measur
foldchang
pair
test
p
rang
among
identifi
gene
gene
largest
foldchang
express
acut
stage
recoveri
stage
ard
foldchang
gene
encod
neutrophil
elastas
inhibitor
peptidas
inhibitor
formal
call
elafin
one
two
lowmolecularweight
proteas
inhibitor
antileukoproteas
famili
previou
report
local
injuri
site
addit
antiproteinas
activ
protein
also
demonstr
antimicrobi
antiinflammatori
activ
compar
recoveri
stage
ard
gene
express
chang
lower
level
peripher
blood
acut
stage
ard
tabl
suggest
gene
product
could
play
import
role
develop
ard
investig
role
earli
develop
ard
investig
plasma
level
among
three
ard
sampl
group
prediagnosi
group
dayofdiagnosi
group
postdiagnosi
group
well
ard
sampl
group
atrisk
control
subject
demograph
character
patient
shown
tabl
descript
characterist
significantli
differ
ard
case
control
subject
except
ard
case
frequent
receiv
pack
red
blood
cell
transfus
p
addit
patient
ard
atrisk
control
subject
statist
signific
differ
gene
ontolog
biolog
process
significantli
enrich
list
gene
identifi
pair
test
p
multipl
comparison
adjust
bonferroni
correct
baselin
characterist
select
subject
rest
studi
popul
data
shown
plasma
level
statist
signific
differ
among
three
ard
sampl
group
anova
p
among
four
sampl
group
includ
first
sampl
control
subject
anova
p
trend
decreas
plasma
level
prediagnosi
group
postdiagnosi
group
shown
figur
postdiagnosi
group
lowest
plasma
level
mean
pgml
confid
interv
ci
pgml
statist
significantli
lower
prediagnosi
group
mean
pgml
ci
pgml
p
significantli
differ
dayofdiagnosi
group
mean
pgml
ci
pgml
adjust
multipl
comparison
p
plasma
level
postdiagnosi
group
significantli
differ
atrisk
control
subject
collect
first
hour
icu
admiss
p
among
three
ard
group
prediagnosi
group
highest
plasma
level
significantli
higher
first
sampl
control
subject
collect
first
hour
icu
admiss
mean
pgml
ci
pgml
adjust
multipl
comparison
p
also
test
trend
plasma
decreas
across
ard
develop
measur
sampl
date
rel
ard
diagnosi
pearson
correl
coeffici
p
use
stepwis
multivari
linear
regress
model
besid
sampl
date
rel
ard
diagnosi
pneumonia
partial
r
p
lowest
level
hematocrit
icu
admiss
partial
r
p
significantli
relat
plasma
level
without
forc
covari
stepwis
multivari
linear
regress
analysi
pick
three
covari
regress
model
explain
interindividu
variabl
plasma
level
sampl
date
rel
ard
diagnosi
alon
explain
total
varianc
mean
regress
slope
fold
chang
plasma
ci
p
furthermor
extra
covari
includ
age
sex
apach
iii
score
icu
admiss
histori
steroid
use
sepsi
septic
shock
diabet
chronic
liver
diseas
trauma
ad
model
remain
signific
p
r
increas
contrast
statist
signific
differ
exist
plasma
level
among
three
ard
sampl
group
anova
p
among
four
sampl
group
includ
first
sampl
control
anova
p
expect
base
lack
chang
chang
p
microarray
analysi
figur
addit
atrisk
control
subject
found
statist
signific
increas
plasma
level
mean
fold
chang
plasma
level
ci
p
day
first
hour
icu
admiss
figur
figur
comparison
express
foldchang
select
gene
measur
microarray
quantit
rtpcr
pair
rna
sampl
use
microarray
analysi
pair
enough
rna
quantit
rtpcr
analysi
includ
patient
acut
respiratori
distress
syndrom
ard
control
subject
gene
hpgd
chosen
larg
differenti
express
acut
stage
stabl
stage
ard
well
identifi
repeatedli
medlin
literatur
mine
gene
margin
express
chang
gene
chang
chosen
refer
gene
valid
result
gene
actb
also
illustr
origin
select
endogen
control
yaxi
display
fold
chang
recoveri
stage
acut
stage
ard
use
microarraybas
global
gene
profil
whole
blood
total
rna
identifi
gene
alter
express
acut
stage
recoveri
stage
subject
ard
base
gene
ontolog
annot
ardsrel
gene
express
chang
cluster
go
biolog
process
relat
respons
stimulu
go
death
go
signific
subordin
go
term
death
among
identifi
gene
found
gene
largest
differenti
express
peripher
blood
patient
ard
express
gene
suppress
earli
acut
stage
ard
compar
significantli
higher
level
recoveri
stage
ard
gene
encod
protein
peptidas
inhibitor
two
isoform
includ
acid
molecul
name
preelafin
also
known
acid
molecul
call
elafin
produc
proteolyt
cleavag
preelafin
preelafin
elafin
two
function
domain
includ
ctermin
domain
contain
antiproteinas
activ
site
ntermin
domain
contain
motif
transglutaminas
substrat
transglutaminas
substrat
motif
five
motif
preelafin
molecul
one
motif
elafin
enabl
coval
bind
proteinas
inhibitor
extracellular
matrix
ecm
protein
protein
express
induc
inflammationiniti
cytokin
local
site
inflammatori
respons
includ
airway
skin
mucos
surfac
howev
studi
found
express
gene
peripher
blood
differenti
express
acut
stage
recoveri
stage
ard
importantli
microarray
find
lower
gene
express
acut
stage
ard
well
correl
result
elisa
assay
measur
plasma
level
found
express
lowest
level
plasma
acut
stage
compar
plasma
level
prediagnosi
day
ard
diagnosi
moreov
time
cours
plasma
decreas
also
well
correl
cours
earli
ard
develop
plasma
sampl
date
rel
ard
diagnosi
show
moder
neg
correl
plasma
level
pearson
correl
coeffici
p
also
largest
contribut
explain
plasma
varianc
partial
r
multivari
linear
regress
model
furthermor
seem
preonset
increas
plasma
level
prediagnosi
ard
group
mean
pgml
c
pgml
p
compar
atrisk
control
within
first
icu
admiss
mean
pgml
c
pgml
even
though
reach
significantli
level
multipl
comparison
adjust
contrast
signific
moder
increas
plasma
level
period
icu
admiss
atrisk
control
subject
mean
fold
chang
plasma
level
ci
p
figur
taken
togeth
observ
suggest
level
plasma
could
use
biomark
monitor
develop
progress
ard
similarli
earlier
studi
report
serum
level
elafin
could
use
monitor
diseas
activ
psoriasi
inflammatori
skin
joint
diseas
serum
elafin
level
correl
clinic
cours
psoriasi
diseas
sever
score
psoriasi
area
sever
index
decreas
serum
elafin
level
associ
respons
cyclosporin
treatment
neutrophil
play
crucial
role
initi
propag
ard
consider
evid
exist
role
neutrophilderiv
proteinas
pathogenesi
ard
includ
neutrophil
elastas
collagenas
local
imbal
proteinas
physiolog
inhibitor
result
pulmonari
parenchyma
damag
leakag
proteinrich
fluid
interstitium
alveolar
space
major
pulmonari
proteinas
inhibitor
includ
proteinas
inhibitor
secretori
leukocyt
proteinas
inhibitor
slpi
elafin
unlik
highmolecularweight
mainli
produc
liver
reach
lung
via
passiv
diffus
slpi
lowmolecularweight
inhibitor
produc
local
neutrophil
infiltr
site
lung
slpi
import
antiproteinas
lung
health
diseas
also
demonstr
multipl
biolog
function
antibacteri
activ
antiinflammatori
activ
prime
innat
immun
tissu
remodel
cellular
differenti
augment
antivir
adapt
immun
contrari
extens
molecular
character
limit
studi
directli
investig
potenti
protect
effect
acut
lung
injuri
ali
ard
murin
model
lung
injuri
mediat
pseudomona
aeruginosa
intratrach
administr
human
elafin
encod
adenoviru
vector
show
signific
protect
lung
injuri
reduc
protein
concentr
bal
fluid
increas
elimin
bacteria
airway
decreas
incid
hematogen
bacteri
dissemin
anoth
studi
tremblay
cowork
recombin
human
preelafin
exhibit
signific
protect
effect
human
neutrophil
elastas
hne
induc
acut
lung
injuri
hamster
dosedepend
manner
contrast
preelafin
elafin
show
protect
effect
within
studi
elafin
proteolyt
product
preelafin
contain
less
transglutaminas
substrat
motif
preelafin
elafin
could
crosslink
ecm
protein
catalyz
transglutaminas
still
exert
antiproteinas
function
howev
addit
transglutaminas
substrat
motif
contain
preelafin
might
allow
stronger
bind
local
inflammatori
site
show
stronger
protect
effect
elafin
current
one
report
measur
bal
level
slpi
well
human
popul
although
signific
increas
observ
among
patient
ard
atrisk
patient
without
ard
compar
healthi
individu
signific
differ
patient
ard
atrisk
patient
without
ard
contrast
slpi
demonstr
signific
increas
two
patient
group
furthermor
almost
detect
associ
highmolecularweight
protein
reveal
western
blot
analysi
believ
differ
slpi
bal
could
partial
explain
uniqu
structur
transglutaminas
substrat
motif
contain
protein
allow
coval
bind
ecm
protein
anchor
lung
parenchyma
exert
biolog
function
local
may
imposs
assess
accur
protect
role
ali
ard
bal
fluid
lung
tissu
also
found
gene
larg
differenti
express
peripher
blood
patient
ard
similar
pattern
gene
potent
neutrophil
chemoattract
associ
ard
number
previou
studi
markedli
increas
level
consist
found
bal
fluid
patient
ard
strong
correl
number
bal
neutrophil
suggest
play
major
role
promot
lung
damag
persist
increas
bal
level
also
associ
poor
clinic
prognosi
unlik
previou
studi
found
gene
express
suppress
earli
acut
stage
ard
compar
recoveri
stage
studi
howev
previou
studi
mainli
focus
measur
level
bal
fluid
fewer
report
includ
measur
peripher
blood
patient
ard
compar
healthi
control
subject
callist
colleagu
report
signific
higher
level
plasma
patient
mix
aliard
p
focus
earli
stage
ard
develop
goodman
cowork
observ
margin
signific
increas
plasma
level
six
patient
p
within
hour
posttraumat
ard
wide
concentr
rang
healthi
control
subject
anoth
studi
serum
measur
first
hour
ard
signific
differ
ard
ali
contrast
significantli
elev
level
bal
fluid
ard
studi
also
report
concentr
bal
fluid
pulmonari
epitheli
line
fluid
significantli
higher
serum
level
ard
ali
control
subject
indic
signific
correl
pulmonari
blood
level
consid
mani
factor
associ
underli
caus
ard
could
affect
plasma
level
investig
plasma
level
current
studi
studi
abl
uniqu
investig
decreas
plasma
along
earli
ard
develop
specif
preto
postard
diagnosi
worth
note
drawback
avail
ard
plasma
sampl
repres
differ
patient
instead
ideal
longitudin
sampl
patient
howev
observ
decreas
plasma
like
sole
associ
ard
risk
factor
sepsi
trauma
regress
model
remain
signific
adjust
import
clinic
covari
ard
signific
differ
risk
factor
patient
ard
atrisk
control
subject
studi
popul
addit
observ
coincid
lower
gene
express
lower
plasma
level
acut
stage
ard
addit
studi
need
address
whether
varianc
plasma
level
mere
driven
express
chang
gene
blood
cell
reflect
differ
level
lung
conclus
studi
first
report
decreas
peripher
blood
associ
earli
ard
develop
suggest
circul
may
provid
use
clinic
marker
monitor
earli
develop
ard
may
signific
implic
ard
treatment
